China Regenerative Medicine International Management
Management criteria checks 4/4
China Regenerative Medicine International's CEO is Chuang Wang, appointed in Jul 2020, has a tenure of 3.83 years. directly owns 24.28% of the company’s shares, worth HK$13.45M. The average tenure of the management team and the board of directors is 4.7 years and 4.3 years respectively.
Key information
Chuang Wang
Chief executive officer
HK$1.2m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.8yrs |
| CEO ownership | 24.3% |
| Management average tenure | 4.7yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Little Excitement Around China Regenerative Medicine International Limited's (HKG:8158) Revenues As Shares Take 32% Pounding
Mar 05
China Regenerative Medicine International Limited's (HKG:8158) Price Is Right But Growth Is Lacking After Shares Rocket 57%
Jan 04These 4 Measures Indicate That China Regenerative Medicine International (HKG:8158) Is Using Debt Extensively
Sep 21China Regenerative Medicine International Limited (HKG:8158) May Have Run Too Fast Too Soon With Recent 31% Price Plummet
Jun 11Is China Regenerative Medicine International (HKG:8158) A Risky Investment?
May 22Is China Regenerative Medicine International (HKG:8158) A Risky Investment?
Apr 13Does China Regenerative Medicine International (HKG:8158) Have A Healthy Balance Sheet?
Sep 22Introducing China Regenerative Medicine International (HKG:8158), The Stock That Zoomed 142% In The Last Year
Mar 16What Is The Ownership Structure Like For China Regenerative Medicine International Limited (HKG:8158)?
Feb 08Trade Alert: The CEO & Executive Chairman Of China Regenerative Medicine International Limited (HKG:8158), Chuang Wang, Has Just Spent HK$55m Buying 428% More Shares
Dec 15
Don't Ignore The Fact That This Insider Just Sold Some Shares In China Regenerative Medicine International Limited (HKG:8158)
Nov 25Does China Regenerative Medicine International (HKG:8158) Have A Healthy Balance Sheet?
Nov 24CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -HK$108m |
| Sep 30 2023 | n/a | n/a | HK$677k |
| Jun 30 2023 | n/a | n/a | HK$15m |
| Mar 31 2023 | n/a | n/a | HK$5m |
| Dec 31 2022 | HK$1m | n/a | HK$5m |
| Sep 30 2022 | n/a | n/a | HK$31m |
| Jun 30 2022 | n/a | n/a | HK$26m |
| Mar 31 2022 | n/a | n/a | HK$49m |
| Dec 31 2021 | HK$1m | n/a | HK$52m |
| Sep 30 2021 | n/a | n/a | -HK$95m |
| Jun 30 2021 | n/a | n/a | -HK$82m |
| Mar 31 2021 | n/a | n/a | -HK$105m |
| Dec 31 2020 | HK$1m | n/a | -HK$120m |
| Sep 30 2020 | n/a | n/a | -HK$201m |
| Jun 30 2020 | n/a | n/a | -HK$237m |
| Mar 31 2020 | n/a | n/a | -HK$239m |
| Dec 31 2019 | HK$245k | HK$245k | -HK$264m |
Compensation vs Market: Chuang's total compensation ($USD153.54K) is below average for companies of similar size in the Hong Kong market ($USD232.74K).
Compensation vs Earnings: Chuang's compensation has been consistent with company performance over the past year.
CEO
Chuang Wang (44 yo)
3.8yrs
Tenure
HK$1,200,000
Compensation
Mr. Chuang Wang has been Executive Chairman at China Regenerative Medicine International Limited since October 18, 2019 and serves as its Chief Executive Officer since July 9, 2020 and also serves as its C...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Executive Chairman & Compliance Officer | 3.8yrs | HK$1.20m | 24.28% HK$ 13.7m | |
| Chief Financial Officer | 1.7yrs | no data | no data | |
| Chief Operating Officer | 5.6yrs | no data | no data | |
| Chief Technology Officer | 5.7yrs | no data | no data | |
| Legal Counsel | no data | no data | no data | |
| Chairman of Stem Cell Division & Director of University of Oxford Tissue Engineering Centre | 5.7yrs | HK$500.00k | no data | |
| Company Secretary | 1.7yrs | no data | no data |
4.7yrs
Average Tenure
44yo
Average Age
Experienced Management: 8158's management team is considered experienced (4.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Executive Chairman & Compliance Officer | 4.6yrs | HK$1.20m | 24.28% HK$ 13.7m | |
| Independent Non-Executive Director | 2.4yrs | HK$120.00k | no data | |
| Non-Executive Director | 4.3yrs | HK$314.00k | no data | |
| Independent Non-Executive Director | 4.3yrs | HK$120.00k | no data | |
| Independent Non-Executive Director | 2.4yrs | HK$120.00k | no data |
4.3yrs
Average Tenure
48yo
Average Age
Experienced Board: 8158's board of directors are considered experienced (4.3 years average tenure).